Sinopharm needs trial results to decide if COVID-19 vaccine needs booster shot
|
|
Sinopharm needs trial results to decide if COVID-19 vaccine needs booster shot
本帖最後由 geemong 於 2021-3-29 17:18 編輯
Sinopharm needs trial results to decide if COVID-19
vaccine needs booster shot
China National Pharmaceutical Group (Sinopharm) will need to assess results from
overseas Phase III clinical trials to decide whether its two-shot COVID-19 vaccine
should be followed by a booster shot, a company executive said on Sunday
(Mar 28).
Regulators and สล็อตออนไลน์ SLOTXO งบจำกัดเล่นได้ กำไรดี vaccine developers
are looking at whether booster doses are necessary amid concerns that emerging
variants of the new coronavirus might weaken protection of vaccines designed
against older strains.
"The preliminary results so far showed that the booster vaccination can effectively
increase the neutralising antibody titer and antibody persistence, and also
effectively improve the vaccine's ability to resist mutations," Zhang Yuntao,
vice president at China National Biotec Group (CNBG), an affiliate of Sinopharm,
said on Sunday.
"Is a booster shot needed? When will the booster be given? The answer should be
based on the results of future phase III clinical studies," Zhang said at a news
conference.
Antibodies triggered by two COVID-19 vaccine products from Sinopharm both have
"pretty good" neutralising effect on variants found in Britain and South Africa as
well as a few others, Zhang told a news conference, citing results from lab tests
using blood samples taken from clinical trial participants.
Lab testing was ongoing for variants found in Brazil and Zimbabwe, Zhang said.
The effect of antibodies induced by Sinovac Biotech's vaccine declined against
a variant identified in South Africa, while the effect against a variant found in Britain
remained similar to that against the older Wuhan variant, Gao Qiang, general
manager at Sinovac unit Sinovac Life Sciences, said during the same presser.
Sinovac is importing the variant from Brazil for vaccine research and development,
and work tailored to the South Africa variant had already started, Gao said.
The correlation between antibody levels and the vaccine's efficacy was not
immediately clear, a Sinovac spokesman said. |
|
|
|
|
|
